See more : Nanjing Railway New Technology Co.,Ltd. (301016.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of CanSino Biologics Inc. (688185.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CanSino Biologics Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Archidply Decor Limited (ADL.BO) Income Statement Analysis – Financial Results
- VCU Data Management Limited (VCU.BO) Income Statement Analysis – Financial Results
- Y.U.D.Yangtze River Investment Industry Co.,Ltd. (600119.SS) Income Statement Analysis – Financial Results
- ReneSola Ltd (SOL) Income Statement Analysis – Financial Results
- MT Educare Limited (MTEDUCARE.BO) Income Statement Analysis – Financial Results
CanSino Biologics Inc. (688185.SS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cansinotech.com
About CanSino Biologics Inc.
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 345.18M | 1.03B | 4.30B | 18.54M | 2.28M | 1.13M | -602.32K | 8.20M |
| Cost of Revenue | 1.22B | 1.22B | 1.30B | 13.80M | 147.46K | 113.65M | 68.10M | 51.67M |
| Gross Profit | -876.02M | -186.61M | 3.00B | 4.74M | 2.14M | -112.51M | -68.70M | -43.47M |
| Gross Profit Ratio | -253.78% | -18.10% | 69.85% | 25.56% | 93.54% | -9,939.40% | 11,406.28% | -530.47% |
| Research & Development | 637.99M | 778.26M | 878.72M | 428.49M | 151.75M | 113.65M | 68.10M | 51.67M |
| General & Administrative | 294.45M | 278.07M | 231.81M | 82.88M | 62.79M | 20.61M | 3.19M | 1.81M |
| Selling & Marketing | 353.40M | 266.61M | 105.82M | 16.56M | 5.29M | 0.00 | 0.00 | 0.00 |
| SG&A | 647.85M | 544.68M | 337.63M | 99.44M | 68.07M | 20.61M | 3.19M | 1.81M |
| Other Expenses | -126.67M | -60.98M | -15.00M | -82.86M | -15.61M | 100.00K | -1.77M | 13.40M |
| Operating Expenses | 1.16B | 1.26B | 1.20B | 445.06M | 204.21M | 152.35M | 75.60M | 54.36M |
| Cost & Expenses | 2.38B | 2.48B | 2.50B | 458.87M | 204.21M | 152.35M | 75.60M | 54.36M |
| Interest Income | 100.06M | 65.93M | 79.65M | 31.72M | 21.85M | 205.00K | 228.00K | 150.00K |
| Interest Expense | 64.15M | 41.34M | 20.42M | 7.02M | 8.98M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 269.05M | 196.36M | 88.54M | 31.82M | 22.45M | 11.95M | 8.49M | 6.40M |
| EBITDA | -1.65B | -945.81M | 2.05B | -364.68M | -134.24M | -126.26M | -55.93M | -47.96M |
| EBITDA Ratio | -477.05% | -99.82% | 45.98% | -2,173.04% | -6,041.45% | -12,261.93% | 11,251.33% | -550.67% |
| Operating Income | -2.04B | -1.37B | 1.91B | -440.32M | -202.07M | -138.58M | -63.80M | -52.69M |
| Operating Income Ratio | -589.60% | -132.75% | 44.46% | -2,374.48% | -8,849.65% | -12,241.87% | 10,591.71% | -642.90% |
| Total Other Income/Expenses | 56.30M | 184.74M | 25.18M | 43.69M | 45.31M | 297.00K | -654.00K | 2.84M |
| Income Before Tax | -1.98B | -1.18B | 1.94B | -396.64M | -156.77M | -138.28M | -64.45M | -49.85M |
| Income Before Tax Ratio | -573.29% | -114.84% | 45.04% | -2,138.90% | -6,865.49% | -12,215.64% | 10,700.29% | -608.31% |
| Income Tax Expense | -11.45M | -219.24M | 29.70M | -38.15M | -3.66M | 12.94M | -654.00K | 2.84M |
| Net Income | -1.48B | -964.76M | 1.91B | -358.49M | -153.11M | -138.28M | -64.45M | -49.85M |
| Net Income Ratio | -429.55% | -93.57% | 44.52% | -1,933.19% | -6,705.33% | -12,215.64% | 10,700.29% | -608.31% |
| EPS | -6.01 | -3.91 | 7.74 | -1.45 | -0.62 | -0.63 | -0.30 | -0.23 |
| EPS Diluted | -6.01 | -3.91 | 7.74 | -1.45 | -0.62 | -0.63 | -0.30 | -0.23 |
| Weighted Avg Shares Out | 246.71M | 246.77M | 247.45M | 247.45M | 247.45M | 218.20M | 218.20M | 218.20M |
| Weighted Avg Shares Out (Dil) | 246.71M | 246.77M | 247.45M | 247.45M | 247.45M | 218.20M | 218.20M | 218.20M |
Source: https://incomestatements.info
Category: Stock Reports